In summary, our study not only confirms the elevation of CSRP2 expression in GBM, but also demonstrates that CSRP2 promotes GBM malignancy, including its PMT and TMZ resistance through interacting with p130Cas, thereby activating the NF-κB and the MAPK signaling pathways. This evidence concerns the gene CSRP2 and glioblastoma.